Abstract | AIMS: METHODS AND RESULTS: This study included 4570 patients with coronary artery disease enrolled in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment trial and randomized to receive bivalirudin or heparin. Primary outcomes were in-hospital incidence of major bleeding and 30-day incidence of myocardial infarction. Major bleeding, myocardial infarction, and bleeding plus myocardial infarction occurred in 140, 204, and 34 patients, respectively. Older age, female sex, lower body weight, low cholesterol, multi-lesion intervention, complex lesions, and heparin therapy were independent correlates of increased risk of bleeding. Multi-lesion intervention, unstable angina, and lower body weight correlated independently with increased risks of myocardial infarction. Compared with heparin, bivalirudin was associated with a reduction in major bleeding (3.1 vs. 4.6%, P = 0.008), but mostly in low-risk patients. A reduction in the bleeding risk inversely correlated with an increase in the risk of myocardial infarction with bivalirudin (R = -0.61). CONCLUSION:
|
Authors | Raisuke Iijima, Gjin Ndrepepa, Julinda Mehilli, Robert A Byrne, Stefanie Schulz, Franz-Josef Neumann, Gert Richardt, Peter B Berger, Albert Schömig, Adnan Kastrati |
Journal | European heart journal
(Eur Heart J)
Vol. 30
Issue 3
Pg. 290-6
(Feb 2009)
ISSN: 1522-9645 [Electronic] England |
PMID | 19147609
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Hirudins
- Peptide Fragments
- Recombinant Proteins
- Heparin
- bivalirudin
|
Topics |
- Aged
- Aged, 80 and over
- Angioplasty, Balloon, Coronary
(adverse effects, methods)
- Anticoagulants
(adverse effects, therapeutic use)
- Coronary Disease
(diagnostic imaging, therapy)
- Double-Blind Method
- Female
- Hemorrhage
(etiology)
- Heparin
(adverse effects, therapeutic use)
- Hirudins
(adverse effects)
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(etiology, prevention & control)
- Peptide Fragments
(adverse effects, therapeutic use)
- Radiography
- Recombinant Proteins
(adverse effects, therapeutic use)
- Risk Factors
|